Rights and permissions
About this article
Cite this article
Natalizumab undergoing benefit-risk review by EMEA. React. Wkly. 1279, 2 (2009). https://doi.org/10.2165/00128415-200912790-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128415-200912790-00004